Last reviewed · How we verify

NCT05103059

Role of Serum Albumin and Total Protein in Survival of Cancer Cachectic Patients

Status unknown Last updated 2 November 2021
What this trial tests

trial testing BMI in Cancer in 100 participants. Status unknown.

Timeline
1 November 2021
Primary endpoint
1 November 2022
1 December 2022

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 November 2021
Primary completion1 November 2022
Estimated completion1 December 2022

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Serum albumin can indicate the onset of cancer cachexia, provide information about a patient's nutritional status, and serve as a biomarker for the prognosis of patients with cancer cachexia. However, the relationship between serum albumin levels and mortality in patients with cancer cachexia remains unclear. We aimed to examine the association of albumin and total protein with 1-year mortality in patients with cancer cachexia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of BMI

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05103059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing